Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Lusutrombopag in Adult Subjects With Relapsed Persistent or Chronic ITP
NCT01129024Phase 2Terminated
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Apr 2010
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lusutrombopag in immune thrombocytopenia (ITP), sponsored by Shionogi & Co., Ltd. Primary endpoint: Number of Participants With Adverse Events up to 3 years. Started Apr 2010; status: terminated.
02
Drugs
lusutrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT01129024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01129024.